K
Kevin Foley
Researcher at GlaxoSmithKline
Publications - 79
Citations - 3393
Kevin Foley is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Hsp90 inhibitor & Cancer. The author has an hindex of 26, co-authored 72 publications receiving 3006 citations. Previous affiliations of Kevin Foley include Fred Hutchinson Cancer Research Center & ZymoGenetics.
Papers
More filters
Journal ArticleDOI
Results of the prospective, randomized, multicenter food and drug administration investigational device exemption study of the prodisc®-L total disc replacement versus circumferential fusion for the treatment of 1-level degenerative disc disease
Jack Zigler,Rick B. Delamarter,Jeffrey M. Spivak,Raymond Linovitz,Guy O. Danielson,Thomas Haider,Frank P. Cammisa,Jim Zuchermann,Richard A. Balderston,Scott H. Kitchel,Kevin Foley,Robert G. Watkins,David S. Bradford,James J. Yue,Hansen Yuan,Harry N. Herkowitz,Doug Geiger,John A. Bendo,Timothy Peppers,Barton Sachs,Federico P. Girardi,Michael A. Kropf,Jeffrey A. Goldstein +22 more
TL;DR: In this article, the authors evaluated the long-term safety and effectiveness of the ProDisc-L total disc replacement (TDR) as part of an FDA-mandated postmarket approval study.
Journal ArticleDOI
Design of amidobenzimidazole STING receptor agonists with systemic activity
Ramanjulu Joshi M,George Scott Pesiridis,Jingsong Yang,Nestor O. Concha,Robert Singhaus,Shu-Yun Zhang,Jean-Luc Tran,P. Moore,Stephanie Lehmann,H.C. Eberl,Marcel Muelbaier,Jessica L. Schneck,Jim Clemens,Michael Adam,John F. Mehlmann,Joseph J. Romano,A. Morales,Jianxing Kang,Lara Kathryn Leister,Todd L. Graybill,Adam Kenneth Charnley,Guosen Ye,Neysa Nevins,K. Behnia,Amaya I. Wolf,Viera Kasparcova,Kelvin Nurse,Liping Wang,Yufeng Li,Michael Klein,Christopher B. Hopson,Jeffrey Guss,Marcus Bantscheff,Giovanna Bergamini,Reilly,Yiqian Lian,Kevin J. Duffy,Jerry L. Adams,Kevin Foley,Peter J. Gough,Robert W. Marquis,James F. Smothers,Axel Hoos,John Bertin +43 more
TL;DR: A linking strategy to synergize the effect of two symmetry-related amidobenzimidazole-based compounds to create linked ABZIs (diABZIs) with enhanced binding to STING and cellular function is developed, representing a milestone in the rapidly growing field of immune-modifying cancer therapies.
Journal ArticleDOI
Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy
Weiwen Ying,Zhenjian Du,Lijun Sun,Kevin Foley,David A. Proia,Ronald K. Blackman,Dan Zhou,Takayo Inoue,Noriaki Tatsuta,Jim Sang,Shuxia Ye,Jamie Acquaviva,Luisa Shin Ogawa,Yumiko Wada,James Barsoum,Keizo Koya +15 more
TL;DR: It is shown that ganetespib exhibits potent in vitro cytotoxicity in a range of solid and hematologic tumor cell lines, including those that express mutated kinases that confer resistance to small-molecule tyrosine kinase inhibitors.
Journal Article
Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis.
TL;DR: Results indicate that c-Myc and Mad expression are tightly coupled to the transition from proliferation to differentiation of epithelial cells and that restriction of Mad expression may be associated with loss of normal differentiation capability and with tumorigenesis.
Patent
Triazole compounds that modulate HSP90 activity
Weiwen Ying,David James,Shijie Zhang,Teresa Przewloka,Junghyun Chae,Dinesh Chimmanamada,Chi-Wan Lee,Elena Kostik,Howard P. Ng,Kevin Foley,Zhenjian Du,James Barsoum +11 more
TL;DR: In this paper, the authors proposed methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof, by administering to the subject a substituted triazole compound or a composition comprising such a compound.